Medlab Clinical, the maker of cannabis mouth sprays undergoing testing for effects on cancer, has discovered that its technology can increase the potency of atorvastatin, a cholesterol-lowering drug used to prevent cardiovascular disease.
The company (ASX:MDC) is known for its drug delivery platform NanoCelle, which delivers medicine as tiny particles in a spray to the buccal membrane, or the inside lining of the cheek. Its aim is to make it easier to deliver medicine as well as increase the speed and rate of absorption into the bloodstream.
It has two cannabis drugs in clinical trials — NanaBis, a complementary or replacement treatment for opioids in advanced cancer pain, and NanaBidial, for cancer-induced nausea and seizures.
Medlab recently completed a Phase 1 clinical trial